{"id":"NCT00937859","sponsor":"Serenity Pharmaceuticals, Inc.","briefTitle":"Treatment of Patients With Nocturia","officialTitle":"A Phase III Randomized, Double Blind, Placebo Control, Multicenter Study to Investigate the Efficacy and Safety of SER120 Nasal Spray Formulation in Patients With Nocturia","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-06","primaryCompletion":"2010-07","completion":"2010-07","firstPosted":"2009-07-13","resultsPosted":"2020-09-18","lastUpdate":"2020-09-18"},"enrollment":301,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Nocturia"],"interventions":[{"type":"DRUG","name":"SER120","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"SER120","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to evaluate a treatment of nocturia. The hypothesis is that SER120 will decrease the number of nocturic episodes compared to placebo.","primaryOutcome":{"measure":"Change in Mean Number of Nocturic Episodes/Night","timeFrame":"7 weeks","effectByArm":[{"arm":"SER120","deltaMin":-1.3,"sd":0.9},{"arm":"Placebo","deltaMin":-1.2,"sd":1}],"pValues":[]},"eligibility":{"minAge":"50 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":14},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":148},"commonTop":["Nasal discomfort","Sneezing","Rhinorrhea","Headache","Nasal congestion"]}}